

## REFERENCES

- Capdevila JH, Holla V, Helvig C, Falck JR. Microsomal cytochrome P450 and eicosanoid metabolism *Mol Aspects Med* 1999; 20: 42-55, 56-137.
- Cauffiez C, Lo-Guidice JM, Quaranta S, Allorge D, Chevalier D, Cenee S, et al. Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. *Biochem Biophys Res Commun* 2004; 317: 662-9.
- Cha RS, Zarbl H, Keohavong P, Thilly WG. Mismatch amplification mutation assay (MAMA): application to the c-H-ras gene. *PCR Meth Appl* 1992; 2: 14–20.
- Cheng XY, Chen GL, Zhang WX, Zhou G, Wang D, Zhou HH. Arg257Cys polymorphism of CYP2A13 in a Chinese population. *Clinica Chimica Acta* 2004; 343: 213-6.
- Choudhary D, Jansson I, Sarfarazi M, Schenkman JB. Xenobiotic-metabolizing cytochromes P450 in ontogeny: evolving perspective. *Drug Metab Rev* 2004; 36: 547-66.
- Cloutier JF, Drouin R, Weinfeld M, O'Connor TR, Castonguay A. Characterization and mapping of DNA damage induced by reactive metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) at nucleotide resolution in human genomic DNA. *J Mol Biol* 2001; 313: 539-57.
- Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. *Fundam Clin Pharmacol* 2003; 17: 27-41.

Day DA, Tuite MF. Post-transcriptional gene regulatory mechanisms in eukaryotes:

An overview. *J Endocrinol* 1998; 157: 361-71.

Ding S, Lake G, Friedberg T, Wolf R. Expression and alternative splicing of the cytochrome P-450 CYP2A7. *Biochem J* 1995; 306: 161-6.

Ernster L, Edumi H, Fujii Y, Gelboin HV, Kato R, Sugimura T. Xenobiotics and Cancer. Tokyo: Japan Scientific Societies Press; 1991. p 1-38.

Felicia ND, Rekha GK, Murphy SE. Characterization of cytochrome P450 2A4 and 2A5-catalyzed 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism. *Arch Biochem Biophys* 2000; 384: 418-24.

Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SST, Kimura S, et al. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. *Science* 1995; 268: 722-6.

Fernandez-Salguero P, Gonzalez FJ. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. *Pharmacogenetics* 1995; 5: S123-8.

Fujieda M, Yamasaki Y, Kiyotani K, Muroi A, Kunitoh H, Dosaka-Arita Y, et al. Eighteen novel polymorphisms of the CYP2A13 gene in Japanese. *Drug Metab Pharmacokinet* 2003; 18: 86-90.

Fujita K, Kamataki T. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of *Salmonella typhimurium* YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. *Environ Mol Mutagen* 2001; 38: 339-46.

Gibson GG, Skett P. *Introduction to Drug Metabolism*. 2nd ed. London: Chapman and Hall; 1994.

Gonzalez FJ. Molecular genetics of the P-450 superfamily. *Pharmacol Ther* 1990; 45: 1-38.

Gonzalez FJ. Human cytochrome P450: problems and prospects. *Trends Pharmacol Sci* 1992; 13: 346-52.

Gonzalez FJ, Nebert DW. Evolution of the P450 gene superfamily: animal-plant "Warfare", molecular drive and human genetic differences in drug oxidation. *Trends genet* 1990; 6: 182-6.

Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of carcinogens and toxins. *Drug Metab Rev* 1994; 26: 165-83.

Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. *J Biol Chem* 1992; 267: 83-90.

Gu J, Su T, Chen Y, Zhang Q-Y, Dung X. Expression of biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. *Toxicol Appl Pharmacol* 2000; 165: 158-62.

Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. *Chem Res Toxicol* 1991; 4: 391-407.

Guengerich FP. Metabolisms of chemical carcinogens. *Carcinogenesis* 2000; 21: 345-51.

Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific *N*-nitrosamines. *Chem Res Toxicol* 1998; 11: 559-603.

Hecht SS. Tobacco smoke carcinogens and lung cancer. *J Natl Cancer Inst* 1999; 91: 1194-210.

Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. *Nat Rev Cancer* 2003; 3: 733-44.

Hecht SS, Trushin N, Rigotty J, Carmella SG, Borukhova A, Akerkar S, et al. Inhibitory effects of 6-phenylhexyl isothiocyanate on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone metabolic activation and lung tumorigenesis in rats. *Carcinogenesis* 1996; 17: 2061-7.

Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E. Rapid detection of the *CYP2D6\*3*, *CYP2D6\*4*, and *CYP2D6\*6* allele by tetra-primer PCR and of the *CYP2D6\*5* allele by multiplex long PCR. *Clinical Chemistry* 2000; 46: 1072-7.

Hersberger M, Marti-Jaun J, Hanseler E, Speck RF. Rapid detection of the *CCR2-V64I*, *CCR5-A59029G* and *SDF1-G801A* polymorphisms by tetra-primer PCR. *Clin Biochem* 2002; 35: 399-403.

Hoffman SMG, Fernandez-Sulguero P, Gonzalez FJ, Mohrenweiser HW. Organization and evolution of the cytochromes P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19. *J Molec Evolut* 1995; 41: 894-900.

Hoffman SMG, Nelson DR, Keeney DS, () Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. *Pharmacogenetics* 2001; 11: 687-98.

Hong JY, Ding X, Smith TJ, Coon MJ, Yang CS. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific carcinogen, by rabbit nasal microsomes and cytochrome P450s NMa and NMb. *Carcinogenesis* 1992; 13: 2141-4.

- Hukkanen J, Pelkonen O, Raunio H. Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: possible role in susceptibility for ILD. *Eur Respir J Suppl* 2001; 32: 122s-6s.
- Idle JR. Is environmental carcinogenesis modulated by host polymorphism? *Mutant Res* 1991; 247: 259-66.
- Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. *Mutat Res* 2001; 482: 11-9.
- Jalas JR, Ding X, Murphy SE. Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13. *Drug Metab Dispos* 2003; 31: 1199-202.
- Jalas JR, Hecht SS, Murphy SE. Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. *Chem Res Toxicol* 2005; 18: 95-110.
- Jiang JH, Jia WH, Chen HK, Feng BJ, Qin HD, Pan ZG, et al. Genetic polymorphisms of CYP2A13 and relationship to nasopharyngeal carcinoma in Cantonese population. *J Transl Med* 2004; 2: 24. Available from: <http://www.translational-medicine.com/content/2/1/24>
- Kalow W. Some aspects of the pharmacology of nicotine. *Appl Ther* 1962; 4: 930-2.
- Kiyohara C, Takayama K, Nakanishi Y. CYP2A13, CYP2A6, and the risk of lung adenocarcinoma in a Japanese population. *J Health Sci* 2005; 51: 658-66.
- Klingenberg M. Pigments of rat liver microsomes. *Arch Biochem Biophys* 1958; 75: 376-86.

Koskela S, Hakkola J, Hukkanen J, Pelkonen O, Sorri M, Saranen A, et al.

Expression of CYP2A genes in human liver and extrahepatic tissues.

Biochem Pharmacol 1999; 57: 1407-13.

Kwok S., Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237-38.

Lazarus P, Sheikh SN, Ren Q, Schantz SP, Stern JC, Richie JP Jr, Park JY. p53, but

not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. Carcinogenesis 1998; 19: 509-14.

Mathews DH, Sabina J, Zuckerman M, Turner DH. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure.

J Mol Biol 1999; 288: 911-40.

Mendelman LV, Petruska J, Goodman MF. Base mispair extension kinetics:

Comparison of DNA polymerase alpha and reverse transcriptase. J Biol Chem 1990; 265: 2338-46.

Miles JS, Bickmore W, Brook JD, McLaren AW, Meehan R, Wolf CR. Close linkage

of the human cytochrome P450IIA and P450IIB gene subfamilies: implications for the assignment of substrate specificity. Nucleic Acids Res

1989; 17: 2907-17.

Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA, Wolf CR.

Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J 1990; 267: 365-71.

Morse MA, Lu J, Stoner GD, Murphy SE, Peterson LA. Metabolism of N-nitrosobenzylmethylamine by human cytochrome P-450 enzymes. J Toxicol

Environ Health A 1999; 58: 397-411.

- Murphy SE, Isaac IS, Ding X, McIntee EJ. Specificity of cytochrome P450 2A3-catalyzed alpha-hydroxylation of N-nitrosornicotine enantiomers. *Drug Metab Dispos* 2000; 28: 1263-6.
- Nebert DW. Role of genetics and drug metabolism in human cancer risk. *Mutant Res* 1991; 247: 267-81.
- Nebert DW, Menon AG. Pharmacogenomics, ethnicity, and susceptibility genes. *Pharmacogenomics J* 2001; 11: 19-22.
- Nebert DW, Jones JE, Owens J, Puga A. Evolution of the P450 gene superfamily. *Prog Clin Biol Res* 1988; 274: 557-76.
- Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, et al. The P450 superfamily: update on new sequences, gene mapping, accession number, early trivial names of enzymes, and nomenclature. *DNA Cell Biol* 1993; 12: 1-51.
- Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R., Waxman DJ, et al. P450 Superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. *Pharmacogenetics* 1996; 6: 1-41.
- Newcombe R. Two-sided confidence intervals for the single proportion: comparison of seven methods. *Stat Med* 1998; 17: 857-72.
- Okayama N, Fujimura K, Nakamura J, Suehiro Y, Hamanaka Y, Hinoda Y. Evaluation of new efficient procedure for single-nucleotide polymorphism genotyping: tetra-primer amplification refractory mutation system-polymerase chain reaction. *Clin Chem Lab Med* 2004; 42: 13-6.
- Omura T, Sato R. A new cytochrome in liver microsomes. *J Biol Chem* 1962; 237: 1375-6.

Omura T. Forty years of Cytochrome P450. *Biochem Biophys Res Commun* 1999; 266: 690-8.

Patten CJ, Smith TJ, Murphy SE, Wang MH, Lee J, Tynes RE, et al. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes. *Arch Biochem Biophys* 1996; 333: 127-38.

Pearce R, Greenway D, Parkinson A. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. *Arch Biochem Biophys* 1992; 298: 211-25.

Pelkonen O, Raunio H, Rautio A, Lang M. Xenobiotic-metabolizing enzymes and cancer risk: correspondence between genotype and phenotype. In: Vineis P (ed) *Metabolic Polymorphisms and Susceptibility to cancer*. 1999; 77-88. International Agency for Cancer Research, Lyon.

Peto R, Lopez AD, Boreham J, Thum M, Heath C Jr, Dool R. Mortality from smoking worldwide. *Br Med Bull* 1996; 52: 12-21.

Petruska J, Goodman MF, Boosalis MS, Sowers LC, Cheong C, and Tinoco JJ. Comparison between DNA melting thermodynamics and DNA polymerase fidelity. *Proc Natl Acad Sci* 1988; 85: 6252-6.

Raunio H, Husgafvel-Pursiainen K, Anttila S, Hietanen E, Hirvonen A, Pelkonen O. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility- a review. *Gene* 1995; 159: 113-21.



- Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci USA* 1977; 74: 5463-7.
- Schenkman JB, Choudhary D, Jansson I, Sarfarazi M, Stoilov I. Involvement of cytochromes P450 in development. *Proc Indian Natn Sci Acad* 2003; 69: 917-29.
- Schrader E, Hirsch-Ernst KI, Scholz E, Kahl GF, Foth H. Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in primary cultures of rat alveolar type II cells. *Drug Metab Dispos* 2000; 28: 180-5.
- Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther* 1994; 270: 414-23.
- Su T, Bao Z, Zhang QY, Smith TJ, Hong J-Y, Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. *Cancer Res* 2000; 60: 5074-9.
- Sudo H, Li-Sucholeiki XC, Marcelino LA, Gruhl AN, Zarbl H, Willey JC, et al. Distributions of five common point mutants in the human tracheal-bronchial epithelium. *Mutation Research* 2006; 596: 2113-27.
- Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. *Alimen Pharmacol Ther* 1994; 8 Suppl 1: 33-8.
- von Weymarn LB, Murphy SE. CYP2A13-catalysed coumarin metabolism: comparison with CYP2A5 and CYP2A6. *Xenobiotica* 2003; 33: 73-81.

Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. *Science* 1998; 280: 1077-82.

Wang H, Tan W, Hao B, Miao X, Zhou G, He F, et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. *Cancer Res* 2003; 63: 8057-61.

Wang M, Cheng G, Sturla SJ, Shi Y, McIntee EJ, Villalta PW, et al. Identification of adducts formed by pyridyloxobutylation of deoxyguanosine and DNA by 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone, a chemically activated form of tobacco specific carcinogens. *Chem Res Toxicol* 2003; 16: 616-26.

Wang SL, Lai MD, Huang JD, G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. *Drug Metab Dispos* 1999; 27: 385-88.

Wong HL, Murphy SE, Hecht SS. Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N'-nitrosornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine. *Chem Res Toxicol* 2005; 18: 61-9.

World Health Organization. WHO Mortality Database. Geneva: WHO; 2003.

Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. *Crit Rev Toxicol* 1992; 22: 1-21.

Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. *Arch Toxicol* 1990; 29: 1322-9.

Ye S, Humphries S, Green F. Allele specific amplification by tetra-primer PCR.

Nucleic Acids Research 1992; 20: 1152.

Yun C-H, Shimada T, Guengerich FP. Purification and characterization of human

liver microsomal cytochrome P-450 2A6. Mol Pharmacol 1991; 40: 679-85.

Zhang X, Su T, Zhang QY, Gu J, Gaggana M, Li H, et al. Genetic polymorphisms in

human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J Pharmacol Exp Ther 2002; 302: 416-23.

Zhang X, Chen Y, Liu X, Ren QY, Zhang M, Caggana X, et al. Single nucleotide

polymorphisms of the human CYP2A13 gene: evidence for a null allele. Drug Metab Dispos 2003; 31: 1081-5.

Zhang X, Caggana M, Cutler TL, Ding X. Development of a real-time polymerase

chain reaction-based method for the measurement of relative allelic expression and identification of CYP2A13 alleles with decreased expression in human lung. J Pharmacol Exp Ther 2004; 311: 373-81.

## WWW-pages

<http://www.imm.ki.se/CYPalleles/cyp2a13.htm>


<http://www.drnelson.utm.edu/Cytochrome450.html>

[http://en.wikipedia.org/wiki/Single\\_nucleotide\\_polymorphism](http://en.wikipedia.org/wiki/Single_nucleotide_polymorphism)

[http://www.ornl.gov/sci/techresources/Human\\_Genome/faq/snps.shtml](http://www.ornl.gov/sci/techresources/Human_Genome/faq/snps.shtml)

<http://www.bioinfo.rpi.edu/applications/mfold>

<http://cmpg.unibe.ch/software/htm>



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
Copyright © by Chiang Mai University  
All rights reserved